Topic: neurological disorders
As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives.
As Amgen rides the wave of hype and hope for its early-stage KRAS effort as well as other cancer assets, this is pushing out its work on neuroscience.
Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.
With a new, privately funded research center, Johns Hopkins is trying to jump-start psychedelic research that has been stymied since the 1970s.
The series B round comes 16 months after Viela broke free from AstraZeneca with six drugs and $250 million in funding.
A Harvard-led team has built brain organoids that mimic the cell types and connections that every human brain has.
A cocktail of drugs known as adrenergic receptor antagonists normalized brain potassium levels and restored movement in mice.
Roche and partner PTC Therapeutics are the latest companies to show their hand in improving kids’ ability to move with spinal muscular atrophy.
Skyhawk Therapeutics is teaming up with Takeda to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.
ALS patients on the highest dose of Biogen's tofersen (BIIB067) showed a slowdown in the progression of symptoms in a phase 1 trial.